The ALS Association

North America, District of Columbia, United States, Washington

Description

The ALS Association is the only national non-profit organization fighting Lou Gehrigs Disease on every front.

Investor Profile

The ALS Association has backed more than 12 startups, with 2 new investments in the last 12 months alone. The firm has led 11 rounds, about 92% of its total and boasts 3 exits across its portfolio.

Investment Focus Highlights

Concentrates on Grant, Seed rounds (top funding stages).
Majority of deals are located in United States, France, Spain.
Strong thematic focus on Biotechnology, Health Care, Biopharma.
Led 1 rounds in the past year.

Stage Focus

Grant (92%)
Seed (8%)

Country Focus

United States (50%)
France (17%)
Spain (8%)
United Kingdom (8%)
Israel (8%)
Switzerland (8%)

Industry Focus

Biotechnology
Health Care
Biopharma
Therapeutics
Medical
Pharmaceutical
Neuroscience
Genetics
Artificial Intelligence (Ai)
Cloud Computing

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does The ALS Association frequently co-invest with?

ALS Finding a Cure

North America, Florida, United States, Boynton Beach

Co-Investments: 2

Innosuisse

Europe, Bern, Switzerland, Berne

Co-Investments: 1

What are some of recent deals done by The ALS Association?

Modulo Bio

San Diego, California, United States

Modulo Bio is a biotech company that offers a platform for reprogramming neurocells to improve immunity.

BiopharmaBiotechnologyMedicalProduct Research

GrantFeb 7, 2025

Amount Raised: $500,000

Mabylon AG

Schlieren, Zurich, Switzerland

Biotech from the University of Zurich developing human antibodies to treat neurological diseases and severe allergies.

BiotechnologyHealth CareTherapeutics

GrantSep 24, 2024

Amount Raised: $1,544,769

ProJenX

New Suffolk, New York, United States

ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways.

BiopharmaBiotechnologyHealth CareTherapeutics

GrantJun 20, 2024

Amount Raised: $1,000,000

Coave Therapeutics

Paris, Ile-de-France, France

Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.

BiotechnologyGeneticsLife ScienceNeuroscience

GrantFeb 16, 2024

Myrobalan Therapeutics

Medford, Massachusetts, United States

Myrobalan Therapeutics is a biotech firm that develops oral neurorestorative therapies to reverse key brain dysfunctions and CNS conditions.

BiotechnologyHealth CareTherapeutics

GrantFeb 7, 2024

Amount Raised: $400,000

InFlectis BioScience

Nantes, Pays de la Loire, France

InFlectis BioScience is a private drug discovery company aiming at targeting.

BiopharmaBiotechnologyHealth CareMedicalPharmaceutical

GrantJan 3, 2024

Amount Raised: $943,000

Oryzon Genomics SA

Barcelona, Catalonia, Spain

Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders.

BiopharmaBiotechnologyGeneticsHealth CareMedicalTherapeutics

GrantDec 4, 2023

Amount Raised: $498,690

EverythingALS

Seattle, Washington, United States

EverythingALS is a information technology company that provides services for patients, caregivers, researchers, and drug companies.

Artificial Intelligence (AI)Cloud ComputingInformation TechnologyNon Profit

GrantAug 22, 2023

Amount Raised: $400,000

Tiziana Life Sciences

London, England, United Kingdom

Tiziana Life Sciences is a UK biotechnology company.

Biotechnology

GrantSep 15, 2022

ImmunoBrain Checkpoint

Ness Ziona, HaMerkaz, Israel

ImmunoBrain Checkpoint is a biopharmaceutical company.

BiotechnologyHealth CarePharmaceutical

GrantApr 1, 2020